1 Stock Racing After Walk Test Data

When it comes to developmental drugs, there's a lot of rumors and speculation thrown around about a drug's ultimate success or failure in clinical trials. When the time comes for that hard data, share prices are bound to soar or plummet in a big way. That's what happened today with BioMarin (Nasdaq: BMRN ) , which published phase 3 data around its drug treating an ultra-rare disorder called Morquio A syndrome. Follow along in the video as Brenton Flynn and Max Macaluso discuss today's news and a couple more companies in a similar situation to BioMarin.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.